Recombinant staphylokinase

DRUG5 trials

Sponsors

Supergene, LLC, The First Affiliated Hospital with Nanjing Medical University

Conditions

Acute Myocardial InfarctionIschemic StrokeMyocardial InfarctionST Elevation Myocardial InfarctionST-segment Elevation Myocardial Infarction (STEMI)

Phase 3

Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI

CompletedNCT02301910

Supergene, LLCMyocardial Infarction

Start: 2014-05-16End: 2016-12-01Updated: 2025-03-20

Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS

CompletedNCT03151993

Supergene, LLCIschemic Stroke

Start: 2017-03-18End: 2019-06-20Updated: 2025-04-02

Phase 4

The OPTIMA-5 Trail

CompletedNCT05023681

The First Affiliated Hospital with Nanjing Medical UniversityAcute Myocardial Infarction

Start: 2021-10-29End: 2022-09-14Updated: 2023-01-13

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

RecruitingNCT05410925

The First Affiliated Hospital with Nanjing Medical UniversityST Elevation Myocardial Infarction

Start: 2023-04-08End: 2027-12-31Target: 2260Updated: 2024-10-28

Prolonged Clinical Follow-up of OPTIMA-5

CompletedNCT05649696

The First Affiliated Hospital with Nanjing Medical UniversityST-segment Elevation Myocardial Infarction (STEMI)

Start: 2021-10-29End: 2023-10-01Updated: 2024-09-25

Related Papers

Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction

Circulation Cardiovascular Interventions2024-01-236 citations

Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.

2021-09-0141 citations

254New possibilities of thrombolytic therapy in patients with STEMI according to a multicenter clinical study FRIDOM1

European Heart Journal2019-10-01